Boyden Executive Monitor Finds Building Cybersecurity Teams a Priority as Data Breaches Soar
30.11.2015 11:25 | NASDAQ OMX
NEW YORK and LONDON, 2015-11-30 11:25 CET (GLOBE NEWSWIRE) -- Demand for cybersecurity executives is dramatically increasing as cyberattacks have grown and boards and company leadership sharpen their focus on data security, according to the quarterly Executive Monitor released today byBoyden Global Executive Search.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e0be9bbf-ec0a-4b0a-8e84-c35cdcdec54e
“Organizations are intensively seeking senior cyber talent, though they are having a difficult time finding the right candidates,” said Tim McNamara, Managing Partner, Boyden Washington D.C. and Co-Founder of the firm’s Risk Management & Security sector. “It’s a very complicated sector with bifurcated responsibilities. Consequently, there are multiple strategies to address cybersecurity needs among the commercial, military and defense, and intelligence segments.”
The report covers the rise in Chief Information Security Officer (CISO) and Chief Security Officer (CSO) hiring, the clout of these roles within the executive suite, the need for a balance of technical and management skills, the debate over individual privacy versus collective security, and the mounting risk to corporate and government organizations. The Executive Monitor also includes industry-specific sections on financial services, healthcare and consumer/retail.
"Now more than ever before, because so many high-profile companies have suffered severe security breaches, these critical technical skills are in serious demand to ensure companies are able to save themselves from meltdown,” said Vicky Maxwell Davies, Partner of Boyden UK. “Unfortunately, too many INFOSEC professionals have traditionally come up the audit route and don't combine the tech savvy with the business nous.”
The new report from Boyden also focuses on the following topics affecting cybersecurity and risk management talent acquisition:
- C-suite and board increasing involvement in cybersecurity
- Disconnect between increasing responsibility of CISOs and CSOs versus decision-making authority
- Breaches and cost to corporate reputation
- Cooperation among competitor companies, particularly in financial services
Growth trajectory of the cybersecurity industry to $170 billion by 2020
“It’s the board’s responsibility to challenge management to understand the strategic and systematic nature of an organization’s cyber risk vulnerability and properly allocate resources for risk management,” explained Richard Fudickar, Managing Partner of Boyden Germany. “It’s also important to create awareness holistically within a company, going beyond IT to include all executives, HR and team members to treat data with the highest level of security. Management must understand that this issue is about people and behaviors, not just technology.”
“There has been a great degree of formal and informal cooperation among the large Canadian financial institutions around cybersecurity issues including the sharing of information and best practices,” added Kevin Gormely, Partner of Boyden Toronto. “There is recognition by these organizations, many of which are direct competitors, that they are all likely to be victims of a cybersecurity breach at one time or another.”
The full Boyden Executive Monitor report is available at www.boyden.com.
About Boyden World Corporation
Boyden is a global leader in retained executive search and talent advisory services with more than 70 offices in over 40 countries. Founded in 1946, Boyden specializes in senior executive search, interim management and human capital consulting across a broad spectrum of markets and sectors. For further information, please visit www.boyden.com.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Contacts: Dan Margolis, for Boyden t. +1 (213) 452.6472 e. email@example.com Kara Condon, for Boyden t. firstname.lastname@example.org e. +32 (0)2 289.09.49
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00 | Pressemelding
Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressemelding
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressemelding
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressemelding
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40 | Pressemelding
Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38 | Pressemelding
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom